[
    {
        "pregunta": "1. What are the three diseases that comprise antineutrophil cytoplasmic antibody-associated vasculitides (AAV)?",
        "respuesta": "The three diseases that comprise antineutrophil cytoplasmic antibody-associated vasculitides (AAV) are granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA).",
        "contexto": [
            "2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis  unknown      A7FDDF976624E2E85584FDD8C00804F0 10.1002/acr.24634  INTRODUCTION The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) comprise granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). These diseases affect smalland medium-sized vessels",
            "(oral)</strong><br><strong>Varicella</strong><br><strong>Zoster</strong><br><strong>Yellow fever</strong> | <strong>Granulomatosis with polyangiitis</strong><br><strong>Microscopic polyangiitis</strong><br><strong>Eosinophilic granulomatosis with polyangiitis</strong><br><strong>Giant cell arteritis</strong><br><strong>Polyarteritis nodosa</strong><br><strong>Takayasu arteritis</strong><br><strong>Cryoglobulinemic vasculitis</strong><br><strong>Relapsing",
            "polyangiitis (EGPA). These diseases affect smalland medium-sized vessels and are characterized by multisystem organ involvement. GPA is characterized histologically by necrotizing granulomatous inflammation in addition to vasculitis. Common clinical manifestations include destructive sinonasal lesions, pulmonary nodules, and pauci-immune glomerulonephritis. GPA is most commonly associated with cytoplasmic ANCA and antibodies to proteinase 3 (PR3). Among European populations, prevalence ranges",
            "vasculitis</strong><br><strong>Relapsing polychondritis</strong><br><strong>Behçet's disease</strong><br><strong>Kawasaki disease</strong><br><strong>IgA vasculitis (Henoch-Schönlein)</strong><br><strong>Primary CNS vasculitis</strong><br><strong>Goodpasture's syndrome (anti-GBM)</strong><br><strong>Cogan's syndrome</strong><br><strong>Cutaneous small vessel vasculitis</strong><br><strong>Rheumatoid vasculitis</strong><br><strong>Urticarial vasculitis</strong> |",
            "populations has been estimated to range from 2 to 38 cases per million Prior to the use of alkylating agents, survival with these diseases was quite poor (e.g., median survival of patients with GPA was ~5 months) The Voting Panel was assembled for the ACR and Vasculitis Foundation's broad effort to develop recommendations for 7 forms of systemic vasculitis: giant cell arteritis, Takayasu arteritis, polyarteritis nodosa, Kawasaki syndrome, and the 3 AAVs presented in this report. The physicians"
        ]
    },
    {
        "pregunta": "2. What is the recommended treatment for patients with active, severe GPA/MPA in terms of remission induction therapy?",
        "respuesta": "The recommended treatment for patients with active, severe GPA/MPA in terms of remission induction therapy is treatment with rituximab over cyclophosphamide. This recommendation is based on the evidence provided in the retrieved documents.",
        "contexto": [
            "|Ungraded position statement: For patients with active, severe GPA/MPA, either IV pulse GCs or high-dose oral GCs may be prescribed as part of initial therapy.|2|Very low to moderate|\n|Recommendation: In patients with active, severe GPA/MPA, we conditionally recommend a reduced-dose GC regimen over a standard-dose GC regimen for remission induction.|3|Very low to moderate|\n|Remission induction for active, nonsevere disease| | |",
            "<p>|Recommendation/statement|PICO question informing recommendation and discussion|Level of evidence|\n|---|---|---|\n|Remission induction for active, severe disease| | |\n|Recommendation: For patients with active, severe GPA/MPA, we conditionally recommend treatment with rituximab over cyclophosphamide for remission induction.|4, 5, 6|Very low to moderate|",
            "abstract Table 1 2 1 Remission induction for active, severe disease Recommendation: For patients with active, severe GPA/MPA, we conditionally recommend treatment with rituximab over cyclophosphamide for remission induction. Both rituximab and cyclophosphamide, in combination with glucocorticoids, have been used for remission induction in GPA and MPA. Rituximab has been shown to provide similar benefits to cyclophosphamide for remission induction in a randomized controlled trial",
            "|Recommendation: For patients with severe GPA/MPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, we conditionally recommend treatment with methotrexate or azathioprine over mycophenolate mofetil for remission maintenance.|19|Very low to moderate|",
            "|Ungraded position statement: The duration of GC therapy for GPA/MPA should be guided by the patient’s clinical condition, preferences, and values.|27, 33|Low to moderate|\n|Treatment of disease relapse| | |\n|Recommendation: For patients with GPA/MPA who have experienced relapse with severe disease manifestations and are not receiving rituximab for remission maintenance, we conditionally recommend treatment with rituximab over cyclophosphamide for remission re-induction.|28|Low|"
        ]
    },
    {
        "pregunta": "3. What is the recommended treatment for patients with active, nonsevere GPA in terms of remission induction therapy?",
        "respuesta": "Based on the retrieved documents, the recommended treatment for patients with active, nonsevere GPA in terms of remission induction therapy is to initiate treatment with methotrexate and glucocorticoids (GCs) over cyclophosphamide or rituximab. This recommendation is supported by the evidence provided in the documents.",
        "contexto": [
            "|Remission induction for active, nonsevere disease| | |\n|Recommendation: For patients with active, nonsevere GPA, we conditionally recommend initiating treatment with methotrexate over cyclophosphamide or rituximab.|12, 13|Very low to moderate|\n|Recommendation: For patients with active, nonsevere GPA, we conditionally recommend initiating treatment with methotrexate and GCs over GCs alone.|14|Low|",
            "|Ungraded position statement: For patients with active, severe GPA/MPA, either IV pulse GCs or high-dose oral GCs may be prescribed as part of initial therapy.|2|Very low to moderate|\n|Recommendation: In patients with active, severe GPA/MPA, we conditionally recommend a reduced-dose GC regimen over a standard-dose GC regimen for remission induction.|3|Very low to moderate|\n|Remission induction for active, nonsevere disease| | |",
            "<p>|Recommendation/statement|PICO question informing recommendation and discussion|Level of evidence|\n|---|---|---|\n|Remission induction for active, severe disease| | |\n|Recommendation: For patients with active, severe GPA/MPA, we conditionally recommend treatment with rituximab over cyclophosphamide for remission induction.|4, 5, 6|Very low to moderate|",
            "abstract Table 1 2 1 Remission induction for active, severe disease Recommendation: For patients with active, severe GPA/MPA, we conditionally recommend treatment with rituximab over cyclophosphamide for remission induction. Both rituximab and cyclophosphamide, in combination with glucocorticoids, have been used for remission induction in GPA and MPA. Rituximab has been shown to provide similar benefits to cyclophosphamide for remission induction in a randomized controlled trial",
            "|Recommendation: For patients with active, nonsevere GPA, we conditionally recommend initiating treatment with methotrexate and GCs over azathioprine and GCs or mycophenolate mofetil and GCs.|8, 9, 10|Low|\n|Recommendation: For patients with active, nonsevere GPA, we conditionally recommend initiating treatment with methotrexate and GCs over trimethoprim/sulfamethoxazole and GCs.|11|Low|\n|Remission maintenance| | |"
        ]
    },
    {
        "pregunta": "4. What is the recommended remission maintenance therapy for patients with severe GPA/MPA?",
        "respuesta": "Based on the retrieved documents, the recommended remission maintenance therapy for patients with severe GPA/MPA who have entered remission after treatment with cyclophosphamide or rituximab is treatment with rituximab over methotrexate, azathioprine, mycophenolate mofetil, or leflunomide for remission maintenance. The optimal duration of remission maintenance therapy is not well established and should be guided by the patient's clinical condition, preferences, and values.",
        "contexto": [
            "|Remission maintenance| | |\n|Recommendation: For patients with severe GPA/MPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, we conditionally recommend treatment with rituximab over methotrexate or azathioprine for remission maintenance.|15, 16, 17, 18|Very low to moderate|",
            "|Recommendation: For patients with severe GPA/MPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, we conditionally recommend treatment with methotrexate or azathioprine over mycophenolate mofetil for remission maintenance.|19|Very low to moderate|",
            "|Recommendation: For patients with severe GPA/MPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, we conditionally recommend treatment with methotrexate or azathioprine over leflunomide for remission maintenance.|20|Very low to low|",
            "with impaired vaccine responses Ungraded position statement: The duration of nonglucocor ticoid remission maintenance therapy in GPA/MPA should be guided by the patient's clinical condition, preferences, and values. The optimal duration of remission maintenance therapy is not well established. Although clinical trials have typically administered remission maintenance therapy for ≥18 months, patients may benefit from continuing remission maintenance therapy for a longer duration Ungraded",
            "|Ungraded position statement: The duration of GC therapy for GPA/MPA should be guided by the patient’s clinical condition, preferences, and values.|27, 33|Low to moderate|\n|Treatment of disease relapse| | |\n|Recommendation: For patients with GPA/MPA who have experienced relapse with severe disease manifestations and are not receiving rituximab for remission maintenance, we conditionally recommend treatment with rituximab over cyclophosphamide for remission re-induction.|28|Low|"
        ]
    },
    {
        "pregunta": "5. How should patients with GPA/MPA who have experienced disease relapse with severe manifestations be treated?",
        "respuesta": "Patients with GPA/MPA who have experienced disease relapse with severe manifestations and are not receiving rituximab for remission maintenance should be treated with rituximab over cyclophosphamide for remission re-induction, as per the recommendation provided in the retrieved documents. This recommendation is based on the available evidence and guidelines.",
        "contexto": [
            "|Ungraded position statement: The duration of GC therapy for GPA/MPA should be guided by the patient’s clinical condition, preferences, and values.|27, 33|Low to moderate|\n|Treatment of disease relapse| | |\n|Recommendation: For patients with GPA/MPA who have experienced relapse with severe disease manifestations and are not receiving rituximab for remission maintenance, we conditionally recommend treatment with rituximab over cyclophosphamide for remission re-induction.|28|Low|",
            "|Treatment of refractory disease| | |\n|Recommendation: For patients with severe GPA/MPA that is refractory to treatment with rituximab or cyclophosphamide for remission induction, we conditionally recommend switching treatment to the other therapy over combining the 2 therapies.|30|Very low|</p>",
            "Recommendation: For patients with severe GPA/MPA that is refractory to treatment with rituximab or cyclophosphamide for remission induction, we conditionally recommend switching treatment to the other therapy over combining the 2 therapies. Disease refractory to remission induction therapy is rare, and there are limited data to guide treatment recommendations. Practitioners should evaluate whether other conditions such as infection could be mimicking vasculitis. However, if a patient's disease",
            "|Recommendation: For patients with severe GPA/MPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, we conditionally recommend treatment with methotrexate or azathioprine over mycophenolate mofetil for remission maintenance.|19|Very low to moderate|",
            "|Ungraded position statement: For patients with active, severe GPA/MPA, either IV pulse GCs or high-dose oral GCs may be prescribed as part of initial therapy.|2|Very low to moderate|\n|Recommendation: In patients with active, severe GPA/MPA, we conditionally recommend a reduced-dose GC regimen over a standard-dose GC regimen for remission induction.|3|Very low to moderate|\n|Remission induction for active, nonsevere disease| | |"
        ]
    },
    {
        "pregunta": "6. In what situations is rituximab preferred over cyclophosphamide for remission re-induction in patients with GPA/MPA?",
        "respuesta": "Rituximab is preferred over cyclophosphamide for remission re-induction in patients with GPA/MPA in the following situations:\n1. Patients who previously received cyclophosphamide and then experienced relapse.\n2. Patients who have experienced relapse with severe disease manifestations while receiving rituximab for remission maintenance.\n3. Patients with EGPA who have experienced relapse with severe disease manifestations after prior successful remission induction with rituximab.\n\nThis preference for rituximab over cyclophosphamide is based on the evidence and recommendations provided in the retrieved documents.",
        "contexto": [
            "have experienced relapse with severe disease manifestations and are not receiving rituximab for remission maintenance, we conditionally recommend treatment with rituximab over cyclophosphamide for remission re-induction. Rituximab is more effective than oral cyclophosphamide for reinduction of remission among patients who previously received cyclophosphamide and then experienced relapse, based on subgroup analysis of a randomized controlled trial Recommendation: For patients with GPA/MPA who",
            "randomized controlled trial Recommendation: For patients with GPA/MPA who experienced relapse with severe disease manifestations while receiving rituximab for remission maintenance, we conditionally recommend switching from rituximab to cyclophosphamide over receiving additional rituximab for remission re-induction. Multiple factors can influence whether rituximab or cyclophosphamide treatment (IV or oral) is used, such as time since last rituximab infusion and cumulative cyclophosphamide dose.",
            "abstract Table 1 2 1 Remission induction for active, severe disease Recommendation: For patients with active, severe GPA/MPA, we conditionally recommend treatment with rituximab over cyclophosphamide for remission induction. Both rituximab and cyclophosphamide, in combination with glucocorticoids, have been used for remission induction in GPA and MPA. Rituximab has been shown to provide similar benefits to cyclophosphamide for remission induction in a randomized controlled trial",
            "|Recommendation: For patients with GPA/MPA who experienced relapse with severe disease manifestations while receiving rituximab for remission maintenance, we conditionally recommend switching from rituximab to cyclophosphamide over receiving additional rituximab for remission re-induction.|29|Very low|\n|Treatment of refractory disease| | |",
            "for remission re-induction. Rituximab is favored based on the general desire to avoid re-treatment with cyclophosphamide if possible and on the findings of an observational study of rituximab in relapsing or refractory EGPA Recommendation: For patients with EGPA who have experienced relapse with severe disease manifestations after prior successful remission induction with rituximab, we conditionally recommend treatment with rituximab over switching to cyclophosphamide for remission"
        ]
    },
    {
        "pregunta": "7. What is the recommended treatment for patients with severe GPA/MPA that is refractory to rituximab or cyclophosphamide for remission induction?",
        "respuesta": "The recommendation for patients with severe GPA/MPA that is refractory to rituximab or cyclophosphamide for remission induction is to switch treatment to the other therapy (i.e., if a patient is refractory to rituximab, then cyclophosphamide should be considered, and vice versa) over combining the two therapies. This recommendation is based on the limited data available and the need to explore different treatment options for refractory cases.",
        "contexto": [
            "|Treatment of refractory disease| | |\n|Recommendation: For patients with severe GPA/MPA that is refractory to treatment with rituximab or cyclophosphamide for remission induction, we conditionally recommend switching treatment to the other therapy over combining the 2 therapies.|30|Very low|</p>",
            "Recommendation: For patients with severe GPA/MPA that is refractory to treatment with rituximab or cyclophosphamide for remission induction, we conditionally recommend switching treatment to the other therapy over combining the 2 therapies. Disease refractory to remission induction therapy is rare, and there are limited data to guide treatment recommendations. Practitioners should evaluate whether other conditions such as infection could be mimicking vasculitis. However, if a patient's disease",
            "|Recommendation: For patients with severe GPA/MPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, we conditionally recommend treatment with methotrexate or azathioprine over mycophenolate mofetil for remission maintenance.|19|Very low to moderate|",
            "abstract Table 1 2 1 Remission induction for active, severe disease Recommendation: For patients with active, severe GPA/MPA, we conditionally recommend treatment with rituximab over cyclophosphamide for remission induction. Both rituximab and cyclophosphamide, in combination with glucocorticoids, have been used for remission induction in GPA and MPA. Rituximab has been shown to provide similar benefits to cyclophosphamide for remission induction in a randomized controlled trial",
            "|Recommendation: For patients with GPA/MPA who experienced relapse with severe disease manifestations while receiving rituximab for remission maintenance, we conditionally recommend switching from rituximab to cyclophosphamide over receiving additional rituximab for remission re-induction.|29|Very low|\n|Treatment of refractory disease| | |"
        ]
    },
    {
        "pregunta": "8. What are the recommended therapies for patients with sinonasal, airway, and mass lesions in GPA?",
        "respuesta": "The recommended therapies for patients with sinonasal, airway, and mass lesions in GPA include the following:\n\n1. For patients with sinonasal involvement in GPA, nasal rinses and topical nasal therapies (antibiotics, lubricants, and glucocorticoids) may be beneficial. Collaborating with an otolaryngologist with expertise in treating GPA is suggested to determine whether these interventions should be used.\n\n2. For patients with GPA in remission who have nasal septal defects and/or nasal bridge collapse, reconstructive surgery is conditionally recommended if desired by the patient.\n\n3. For patients with GPA and actively inflamed subglottic and/or endobronchial tissue with stenosis, treating with immunosuppressive therapy is conditionally recommended over surgical dilation with intralesional GC injection alone.\n\n4. For patients with GPA and mass lesions (e.g., orbital pseudotumor or masses of the parotid glands, brain, or lungs), treatment with immunosuppressive therapy is conditionally recommended over surgical removal of the mass lesion with immunosuppressive therapy.\n\nPlease note that the level of evidence for these recommendations ranges from very low to low based on the retrieved documents.",
        "contexto": [
            "<p>|PICO question informing recommendation and discussion|Recommendation/statement|Level of evidence|\n|---|---|---|\n|Treatment of sinonasal, airway, and mass lesions|Ungraded position statement: For patients with sinonasal involvement in GPA, nasal rinses and topical nasal therapies (antibiotics, lubricants, and GCs) may be beneficial.|Very low to low|",
            "For patients with sinonasal involvement in GPA, nasal rinses and topical nasal therapies (antibiotics, lubricants, and GCs) may be beneficial. 36, 37, 38, 39 Very low to low Recommendation: For patients with GPA in remission who have nasal septal defects and/or nasal bridge collapse, we conditionally recommend reconstructive surgery, if desired by the patient. Low Recommendation: For patients with GPA and actively inflamed subglottic and/or endobronchial tissue with stenosis, we conditionally",
            "sinonasal involvement in GPA, nasal rinses and topical nasal therapies (antibiotics, lubricants, and glucocorticoids) may be beneficial. We suggest collaborating with an otolaryngologist with expertise in treating GPA to determine whether these interventions should be used. Recommendation: For patients with GPA in remission who have nasal septal defects and/or nasal bridge collapse, we conditionally recommend reconstructive surgery, if desired by the patient. To optimize surgical outcomes,",
            "| |Recommendation: For patients with GPA in remission who have nasal septal defects and/or nasal bridge collapse, we conditionally recommend reconstructive surgery, if desired by the patient.|Low|\n| |Recommendation: For patients with GPA and actively inflamed subglottic and/or endobronchial tissue with stenosis, we conditionally recommend treating with immunosuppressive therapy over surgical dilation with intralesional GC injection alone.|Low|",
            "subglottic and/or endobronchial tissue with stenosis, we conditionally recommend treating with immunosuppressive therapy over surgical dilation with intralesional GC injection alone. Low Recommendation: For patients with GPA and mass lesions (e.g., orbital pseudotumor or masses of the parotid glands, brain, or lungs), we conditionally recommend treatment with immunosuppressive therapy over surgical removal of the mass lesion with immunosuppressive therapy. 41, 42 Very low to low Other"
        ]
    },
    {
        "pregunta": "9. What considerations should be taken into account when dosing immunosuppressive therapy for patients with GPA/MPA?",
        "respuesta": "Based on the retrieved documents, when dosing immunosuppressive therapy for patients with GPA/MPA, it is recommended to consider the following:\n\n1. Avoid dosing immunosuppressive therapy based solely on ANCA titer results.\n2. Prophylaxis to prevent Pneumocystis jirovecii pneumonia is recommended for patients receiving rituximab or cyclophosphamide.\n3. Consider administering intravenous immunoglobulin (IVIG) for patients with active disease who are unable to receive conventional immunosuppressive therapy.\n4. Evaluate for renal transplantation in patients with GPA/MPA in remission and stage 5 chronic kidney disease.\n5. Balancing the duration of glucocorticoid therapy with the patient's clinical condition, preferences, and values.\n\nThese considerations are based on the evidence and recommendations provided in the retrieved documents.",
        "contexto": [
            "mass lesion with immunosuppressive therapy. 41, 42 Very low to low Other considerations Recommendation: In patients with GPA/MPA, we conditionally recommend against dosing immunosuppressive therapy based on ANCA titer results alone. Very low Recommendation: For patients with GPA who are receiving rituximab or cyclophosphamide, we conditionally recommend prophylaxis to prevent Pneumocystis jirovecii pneumonia. Low Recommendation: For patients with GPA/MPA in remission and stage 5 chronic kidney",
            "similar to those in patients receiving transplants for other reasons, with disease relapses in the transplanted kidney being rare Recommendation: For patients with active GPA/MPA who are unable to receive other immunomodulatory therapy, we conditionally recommend administering IVIG. IVIG should not be used routinely to treat GPA/MPA (see above recommendation). However, in the rare instances in which patients with active disease may not be able to receive conventional immunosuppressive therapy",
            "| |Recommendation: For patients with GPA and mass lesions (e.g., orbital pseudotumor or masses of the parotid glands, brain, or lungs), we conditionally recommend treatment with immunosuppressive therapy over surgical removal of the mass lesion with immunosuppressive therapy.|Very low to low|\n|Other considerations|Recommendation: In patients with GPA/MPA, we conditionally recommend against dosing immunosuppressive therapy based on ANCA titer results alone.|Very low|",
            "continuing remission maintenance therapy for a longer duration Ungraded position statement: The duration of glucocorticoid therapy for GPA/MPA should be guided by the patient's clinical condition, preferences, and values. The optimal duration of glucocorticoid therapy for GPA/MPA is not well established. The immunosuppressive effects of glucocorticoids contributing to disease control should be balanced with the toxicities associated with its use. Overall, patients expressed a desire to minimize",
            "For patients with GPA/MPA in remission and stage 5 chronic kidney disease, we conditionally recommend evaluation for renal transplantation. Low Recommendation: For patients with active GPA/MPA who are unable to receive other immunomodulatory therapy, we conditionally recommend administering IVIG. Low Ungraded position statement: The optimal duration of anticoagulation is unknown for patients with GPA/MPA who experience venous thrombotic events.  Plasma exchange remains advisable in patients"
        ]
    },
    {
        "pregunta": "10. What is the optimal duration of anticoagulation for patients with GPA/MPA who experience venous thrombotic events?",
        "respuesta": "The optimal duration of anticoagulation for patients with GPA/MPA who experience venous thrombotic events is unknown, as indicated in the retrieved documents. Further research and clinical guidelines may be needed to determine the most appropriate duration of anticoagulation in this specific patient population.",
        "contexto": [
            "<h2>| |Ungraded position statement: The optimal duration of anticoagulation is unknown for patients with GPA/MPA who experience venous thrombotic events.|Very low|</h2>\n\n<h1>Key recommendations for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)</h1>",
            "disease may not be able to receive conventional immunosuppressive therapy (e.g., sepsis or pregnancy), IVIG can be used as a short-term intervention until conventional remission induction therapies can be used Ungraded position statement: The optimal duration of anticoagulation is unknown for patients with GPA/MPA who experience venous thrombotic events. AAV is associated with an increased risk of venous thrombotic events, including both deep vein thromboses and pulmonary emboli Recommendations",
            "For patients with GPA/MPA in remission and stage 5 chronic kidney disease, we conditionally recommend evaluation for renal transplantation. Low Recommendation: For patients with active GPA/MPA who are unable to receive other immunomodulatory therapy, we conditionally recommend administering IVIG. Low Ungraded position statement: The optimal duration of anticoagulation is unknown for patients with GPA/MPA who experience venous thrombotic events.  Plasma exchange remains advisable in patients",
            "venous thrombotic events.  Plasma exchange remains advisable in patients with GPA or MPA who also have anti-glomerular basement membrane disease. Recommendation: In patients with active, severe GPA/MPA with alveolar hemorrhage, we conditionally recommend against adding plasma exchange to remission induction therapies. Two trials evaluated the use of plasma exchange in patients presenting with alveolar hemorrhage, and no differences in mortality or remission rates were observed. Thus, plasma",
            "obstetric or thrombotic-should receive therapy with heparin (usually LMWH) to improve pregnancy outcome and/or reduce risk of thrombosis. We strongly recommend combined low-dose aspirin and prophylactic-dose heparin (usually LMWH) for patients meeting criteria for OB APS This is based on evidence of moderate strength. In women with OB APS, we further strongly recommend treating with prophylactic-dose anticoagulation for 6-12 weeks post partum In pregnant women with thrombotic APS, we strongly"
        ]
    }
]